WO2003005034A3 - Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene - Google Patents

Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene Download PDF

Info

Publication number
WO2003005034A3
WO2003005034A3 PCT/CA2002/001004 CA0201004W WO03005034A3 WO 2003005034 A3 WO2003005034 A3 WO 2003005034A3 CA 0201004 W CA0201004 W CA 0201004W WO 03005034 A3 WO03005034 A3 WO 03005034A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
agents useful
processes
treating diseases
diseases involving
Prior art date
Application number
PCT/CA2002/001004
Other languages
English (en)
Other versions
WO2003005034A2 (fr
Inventor
Marcia L Macdonald
Jutta M Zeisler
Mark Samuels
Yigal P Goldberg
Johanne M Robataille
Michael R Hayden
Original Assignee
Xenon Genetics Inc
Univ British Columbia
Marcia L Macdonald
Jutta M Zeisler
Mark Samuels
Yigal P Goldberg
Johanne M Robataille
Michael R Hayden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Genetics Inc, Univ British Columbia, Marcia L Macdonald, Jutta M Zeisler, Mark Samuels, Yigal P Goldberg, Johanne M Robataille, Michael R Hayden filed Critical Xenon Genetics Inc
Publication of WO2003005034A2 publication Critical patent/WO2003005034A2/fr
Publication of WO2003005034A3 publication Critical patent/WO2003005034A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des mutations de gènes sélectionnés tels que le gène 4 de Frizzled ('fzd4'), qui sont les agents responsables de troubles héréditaires de la vue chez l'homme, tels que la vitréorétinopathie exudative familiale ('FEVR'), ainsi que leurs méthodes d'utilisation y compris dans le criblage d'agents thérapeutiques traitant ces maladies et/ou en améliorant les effets, ainsi que sur des procédés de diagnostic de l'état des atteintes à la vue causées par les mutations de ces gènes.
PCT/CA2002/001004 2001-07-05 2002-07-04 Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene WO2003005034A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30328501P 2001-07-05 2001-07-05
US60/303,285 2001-07-05
US34040901P 2001-10-29 2001-10-29
US60/340,409 2001-10-29

Publications (2)

Publication Number Publication Date
WO2003005034A2 WO2003005034A2 (fr) 2003-01-16
WO2003005034A3 true WO2003005034A3 (fr) 2003-05-30

Family

ID=26973372

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2002/001004 WO2003005034A2 (fr) 2001-07-05 2002-07-04 Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene

Country Status (1)

Country Link
WO (1) WO2003005034A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025590A2 (fr) * 2003-09-15 2005-03-24 Develogen Aktiengesellschaft Utilisation d'un produit proteique dg280 dans la prevention et le traitement de troubles metaboliques
DE102004050620A1 (de) * 2004-10-13 2006-04-20 Eberhard-Karls-Universität Tübingen Monoklonaler Antikörper gegen Frizzled-Rezeptoren
CA2590461A1 (fr) * 2004-12-23 2006-06-29 Laboratoires Serono S.A. Polypeptides bcma et leurs utilisations
US20120282230A1 (en) 2009-10-21 2012-11-08 Kimberly Drenser Methods and compositions for diagnosis and treatment of genetic and retinal disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (fr) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS A BASE DU RECEPTEUR DE Wnt ET PROCEDES D'UTILISATION DE CELLES-CI
WO1999026960A2 (fr) * 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes codant des proteines ressemblant a de la frisee
EP1001023A2 (fr) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, un possible récepteur pour Wnt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039357A1 (fr) * 1996-04-12 1997-10-23 The Board Of Trustees Of The Leland Stanford Junior University COMPOSITIONS A BASE DU RECEPTEUR DE Wnt ET PROCEDES D'UTILISATION DE CELLES-CI
WO1999026960A2 (fr) * 1997-11-25 1999-06-03 Millennium Pharmaceuticals, Inc. Genes codant des proteines ressemblant a de la frisee
EP1001023A2 (fr) * 1998-09-09 2000-05-17 Smithkline Beecham Plc Frizzled-4, un possible récepteur pour Wnt

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KIRIKOSHI H ET AL: "MOLECULAR CLONING AND CHARACTERIZATION OF HUMAN FRIZZLED-4 ON CHROMOSOME 11Q14-Q21", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 264, no. 3, 2 November 1999 (1999-11-02), pages 955 - 961, XP001057078, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2003005034A2 (fr) 2003-01-16

Similar Documents

Publication Publication Date Title
WO2003004045A3 (fr) Procedes permettant d'identifier des agents therapeutiques pour traiter des maladies impliquant des polypeptides wnt et des recepteurs wnt
AU2002252373A1 (en) Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
HK1112941A1 (en) Use of a33 antigens and jam-it a33
WO2004065576A3 (fr) Methodes et compositions de traitement de troubles urologiques a l'aide de genes 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 760, 18603,
HK1069767A1 (en) Methods for inhibiting ocular processes
SI1594833T1 (sl) Derivati 1-fenilalkankarboksilne kisline za zdravljenje nevrodegenerativnih bolezni
WO2005108999A3 (fr) Utilisation diagnostique et therapeutique de kcnj6 pour les maladies neurodegeneratives
WO2006125830A3 (fr) Kcnn3 servant de cible diagnostique et therapeutique pour des maladies neurodegeneratives
IL169889A0 (en) Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2004063340A3 (fr) Methodes et compositions pour traiter les maladies cardio-vasculaires au moyen de genes 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612,
WO2006047544A3 (fr) Compositions et procedes de traitement de la maladie d'alzheimer et de troubles associes et procedes favorisant un systeme nerveux sain
WO2003005034A3 (fr) Procedes d'identification d'agents therapeutiques de traitement de maladies impliquant le gene
AU2001251507A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2003050504A3 (fr) Methodes et compositions de traitement d'une maladie cardio-vasculaire a l'aide des genes 1419, 58765 et 2201
WO2004001422A3 (fr) Utilisation, en matiere de diagnostic et de therapie de maladies neurodegeneratives, de la proteine 2 (g3bp2) se fixant au domaine sh3 de la proteine activant la ras gtpase
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
WO2003038130A8 (fr) Solutions therapeutiques et diagnostiques pour les troubles de l'erythropoiese
WO2004003563A3 (fr) Utilisation diagnostique et therapeutique de la proteine et du gene ensadin-0581 dans le cadre des maladies neurodegeneratives
AU2001251508A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
AU2001256998A1 (en) Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
WO2003026566A3 (fr) Atlastine
WO2004038411A3 (fr) Utilisations diagnostique et therapeutique d'un gene de l'ensadin-0289 et d'une proteine pour des maladies neurodegeneratives
WO2004005540A3 (fr) Utilisations de substances qui se lient a ngal pour le diagnostic et le traitement de maladies cancereuses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP